FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783999032> ?p ?o ?g. }

• W2783999032 endingPage "253" @default.
• W2783999032 startingPage "246" @default.
• W2783999032 abstract "Protein structure can be flexible to adopt multiple conformations to house small molecules. In this paper, we have attempted to experimentally figure out how the structure of a transport protein steer the drug-drug competition (DDC) by maintaining the equilibrium distribution of the bound and unbound fractions of drugs. This understanding is an important facet in biophysical and medicinal chemistry to ascertain the effectiveness of drugs. It is important to note that majority of studies involving small-molecule-transport protein interaction aimed at characterizing the binding process, and because these proteins can interact with thousands of molecules, there are hundreds of reports on such interactions. This ultimately led to an impression among the readers that any studies involving serum albumin may not lead to any new findings except for traditional binding explorations. However, in the present paper, we would like to draw the attention of the readers that our findings are very surprising, new, and important, involving the phenomenon of ligand-protein interaction. Here, we have studied two structurally similar drugs methotrexate (MTX) and folic acid (FA), which attempt to bind the primary binding site (subdomain IIA), one at a time, of human serum albumin. Details of binding analyses reveal that when both of the drugs are present, the single-site binding mode of FA prefers to occupy the primary binding site and hence pushes the primary-site-bound MTX to another location (subdomain IIIA), which is the second binding site of MTX. The structural analysis indicates that DDC has occurred in a cooperative fashion so that the loss of the protein secondary structure is minimum when both drugs are bound to the protein, which means that in the case of duo-drug binding, the conventional interaction between the drug and the protein is altered to undergo restoration of the protein structure. This can indeed regulate the DDC by modifying the bound and unbound fractions of MTX in plasma. The present study emphasizes that in vitro structural characterizations of the transport protein provide important information to improve the molecular-level understanding of DDC for further therapeutic applications with combination drug." @default.
• W2783999032 created "2018-01-26" @default.
• W2783999032 creator A5006552894 @default.
• W2783999032 creator A5013245009 @default.
• W2783999032 creator A5014513238 @default.
• W2783999032 date "2018-01-09" @default.
• W2783999032 modified "2023-10-13" @default.
• W2783999032 title "Simultaneous Binding of Folic Acid and Methotrexate to Human Serum Albumin: Insights into the Structural Changes of Protein and the Location and Competitive Displacement of Drugs" @default.
• W2783999032 cites W1504792186 @default.
• W2783999032 cites W1515862194 @default.
• W2783999032 cites W1841512813 @default.
• W2783999032 cites W1965346197 @default.
• W2783999032 cites W1974645077 @default.
• W2783999032 cites W1995666127 @default.
• W2783999032 cites W1997301848 @default.
• W2783999032 cites W2010344733 @default.
• W2783999032 cites W2015228675 @default.
• W2783999032 cites W2016401253 @default.
• W2783999032 cites W2017455283 @default.
• W2783999032 cites W2028181978 @default.
• W2783999032 cites W2064119537 @default.
• W2783999032 cites W2067833741 @default.
• W2783999032 cites W2074952917 @default.
• W2783999032 cites W2081530646 @default.
• W2783999032 cites W2131594279 @default.
• W2783999032 cites W2151081127 @default.
• W2783999032 cites W2152604288 @default.
• W2783999032 cites W2153562492 @default.
• W2783999032 cites W2154125268 @default.
• W2783999032 cites W2157760740 @default.
• W2783999032 cites W2237082602 @default.
• W2783999032 cites W2313847699 @default.
• W2783999032 cites W2328379097 @default.
• W2783999032 cites W2332314294 @default.
• W2783999032 cites W2415218221 @default.
• W2783999032 cites W2491458126 @default.
• W2783999032 cites W2594245371 @default.
• W2783999032 cites W99605343 @default.
• W2783999032 doi "https://doi.org/10.1021/acsomega.7b01437" @default.
• W2783999032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6045412" @default.
• W2783999032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30023775" @default.
• W2783999032 hasPublicationYear "2018" @default.
• W2783999032 type Work @default.
• W2783999032 sameAs 2783999032 @default.
• W2783999032 citedByCount "12" @default.
• W2783999032 countsByYear W27839990322019 @default.
• W2783999032 countsByYear W27839990322020 @default.
• W2783999032 countsByYear W27839990322021 @default.
• W2783999032 countsByYear W27839990322022 @default.
• W2783999032 countsByYear W27839990322023 @default.
• W2783999032 crossrefType "journal-article" @default.
• W2783999032 hasAuthorship W2783999032A5006552894 @default.
• W2783999032 hasAuthorship W2783999032A5013245009 @default.
• W2783999032 hasAuthorship W2783999032A5014513238 @default.
• W2783999032 hasBestOaLocation W27839990321 @default.
• W2783999032 hasConcept C107824862 @default.
• W2783999032 hasConcept C116569031 @default.
• W2783999032 hasConcept C12554922 @default.
• W2783999032 hasConcept C126322002 @default.
• W2783999032 hasConcept C161624437 @default.
• W2783999032 hasConcept C170493617 @default.
• W2783999032 hasConcept C185592680 @default.
• W2783999032 hasConcept C203014093 @default.
• W2783999032 hasConcept C2776125364 @default.
• W2783999032 hasConcept C2778597219 @default.
• W2783999032 hasConcept C2780035454 @default.
• W2783999032 hasConcept C2781059491 @default.
• W2783999032 hasConcept C2992130864 @default.
• W2783999032 hasConcept C51639874 @default.
• W2783999032 hasConcept C55493867 @default.
• W2783999032 hasConcept C71924100 @default.
• W2783999032 hasConcept C86803240 @default.
• W2783999032 hasConcept C96267730 @default.
• W2783999032 hasConcept C98274493 @default.
• W2783999032 hasConceptScore W2783999032C107824862 @default.
• W2783999032 hasConceptScore W2783999032C116569031 @default.
• W2783999032 hasConceptScore W2783999032C12554922 @default.
• W2783999032 hasConceptScore W2783999032C126322002 @default.
• W2783999032 hasConceptScore W2783999032C161624437 @default.
• W2783999032 hasConceptScore W2783999032C170493617 @default.
• W2783999032 hasConceptScore W2783999032C185592680 @default.
• W2783999032 hasConceptScore W2783999032C203014093 @default.
• W2783999032 hasConceptScore W2783999032C2776125364 @default.
• W2783999032 hasConceptScore W2783999032C2778597219 @default.
• W2783999032 hasConceptScore W2783999032C2780035454 @default.
• W2783999032 hasConceptScore W2783999032C2781059491 @default.
• W2783999032 hasConceptScore W2783999032C2992130864 @default.
• W2783999032 hasConceptScore W2783999032C51639874 @default.
• W2783999032 hasConceptScore W2783999032C55493867 @default.
• W2783999032 hasConceptScore W2783999032C71924100 @default.
• W2783999032 hasConceptScore W2783999032C86803240 @default.
• W2783999032 hasConceptScore W2783999032C96267730 @default.
• W2783999032 hasConceptScore W2783999032C98274493 @default.
• W2783999032 hasFunder F4320320767 @default.
• W2783999032 hasFunder F4320334771 @default.
• W2783999032 hasIssue "1" @default.
• W2783999032 hasLocation W27839990321 @default.
• W2783999032 hasLocation W27839990322 @default.

• next